Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study sheds light on CMV treatment in kidney transplant patients

NCT ID NCT06568055

First seen Jan 05, 2026 · Last updated May 19, 2026 · Updated 17 times

Summary

This study reviewed medical records from a UK registry to understand how cytomegalovirus (CMV) infection is managed in adults after a kidney transplant. Researchers looked at data from 330 patients over 7 years to see how common refractory CMV is, what treatments are used, and how well they work. The goal is to improve future care for transplant recipients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • RaDaR (part of the UK Kidney Association)

    Bristol, Southwestern England, United Kingdom

Conditions

Explore the condition pages connected to this study.